Tiny biotech Mapp's Ebola drug thrust into spotlight
This article was originally published in Scrip
Executive Summary
An experimental treatment used in at least two American aid workers infected with the deadly Ebola virus may have helped improve those patients' conditions – thrusting the tiny US biotech that is developing the drug, which has not yet been tested in human clinical trials, into the spotlight.
You may also be interested in...
Playing the Long Game, Partnerships Required For Emerging Infectious Diseases
Bringing drugs and vaccines for emerging infectious diseases to the marketplace requires playing the long game and collaborations if efforts are going to be successful.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.